



www.altpep.com, founded 2018, privately held, HQ Seattle, WA, post Series B funding
contact: Valerie Daggett, PhD CEO and Founder, vdaggett@altpep.com

AltPep is developing a breakthrough approach for early diagnosis and treatment of amyloid disorders.

CHALLENGE

Proteins are an essential part of all living organisms. However, sometimes they unfold, misfold, and accumulate into harmful deposits linked to neurodegenerative and systemic disorders called amyloid diseases. Amyloid diseases affect 1-2 billion people, with societal costs in the trillions and devastating implications for patients and caregivers. Yet, effective diagnostics and treatments have been elusive. Most amyloid diseases lack accurate and early diagnostic tools and current treatment options are often deployed too late – focusing on late-stage symptoms rather than the underlying trigger of the disease.

Research has shown that the seeds of amyloid diseases are planted decades before symptoms surface. Those seeds, toxic soluble oligomers, are small clumps of misfolded proteins that abnormally form in the brain and other organs. There are over 50 amyloid diseases associated with different, misfolded toxic soluble oligomer proteins. These oligomers begin to cause damage to the brain an estimated 10 to 20 years before clinically evident disease - implying the most meaningful opportunity for early intervention and treatment.


ALTPEP'S UNIQUE APPROACH

AltPep has a platform for the early detection and treatment of a host of amyloid-related indications. The technology is based on decades of research and the discovery of a new protein structure, α -sheet, associated with toxic oligomers formed early in amyloidogenesis. These toxic oligomers are the molecular triggers for a variety of downstream events, preceding plaque formation and clinical symptoms.

In response to these discoveries AltPep is developing synthetic peptides specifically tailored to individual indications and applications. These peptides are used to selectively bind, detect, and neutralize the toxic oligomers, thereby targeting the disease in its early stages. This is the basis AltPep's SOBA diagnostics (Soluble Oligomer Binding Assay) and AltPep's SOBIN therapeutics (Soluble Oligomer Binding INhibitors).


FIRST TARGET – ALZHEIMER'S DISEASE (AD)

AltPep's SOBIN-AD therapeutic program (ALT100) is currently in its preclinical phase and is expected to enter the clinic in 2024. AltPep's SOBA-AD diagnostic has received Breakthrough Status from the FDA. This combination is intended to enable early detection of AD combined with neutralization of the toxic oligomers and prevention of neurodegeneration and other downstream events.



BEYOND ALZHEIMER'S DISEASE

Since the initial breakthrough, the broader scope of alpha-sheet has been demonstrated in multiple amyloid diseases as well as innate immunity – with profound and positive implications for human diseases affecting billions around the globe. AltPep has begun development in Parkinson's disease, with other targets on the horizon.



RECENT MILESTONES (2023 to present)

- SOBA-AD identified as one of 5 promising medical studies by NIH in **2023 NIH Research Highlights – Promising Medical Findings**
- Closed \$53M Series B July 2023 – Senator, Section 32, Alexandria Ventures, Matrix, Eli Lilly +
- Moved to new state-of-the-art labs in October 2023, hiring, expanding, accelerating programs
- Expanded Scientific/Clinical Advisory Board
- Determined ALT100 normalizes behavioral and cognitive deficits caused by α -sheet toxic oligomers, and is well tolerated, with good safety profile in multiple mouse studies
- Multiple IND-enabling studies completed and underway in house
- GMP manufacturing complete and drug-product studies in progress
- Pre-IND meeting with FDA in January 2024

RECENT PUBLICATIONS

Nature journal, *Scientific Reports*, “Performance of SOBA-AD blood test in discriminating Alzheimer’s disease patients from cognitively unimpaired controls in two independent cohorts”

<https://www.nature.com/articles/s41598-024-57107-w>

Nature journal, *Scientific Reports*, “Mechanistic insights into the role of amyloid-beta in innate immunity” <https://lnkd.in/gXqermN>

Protein Science, “Human islet amyloid polypeptide-induced B-cell cytotoxicity is linked to formation of alpha-sheet structure”, <https://lnkd.in/eiAhGuR4> (behind paywall)

LEADERSHIP

Board of Directors: <https://www.altpep.com/board-of-directors/>

Scientific/Clinical Advisory Board: <https://www.altpep.com/advisory-board/>

Executive Management: <https://www.altpep.com/leadership/>